The CRISTAL-APC trial is a collaborative initiative that transforms pre-clinical research into a real-world treatment opportunity for patients with advanced pancreatic cancer. The team driving this important work is introduced below.
The trial builds on pioneering research into CCR1 inhibition, led by Dr Mike Gill at the Cancer Research UK Cambridge Institute. His pre-clinical studies showed encouraging results in targeting the tumour microenvironment, laying the essential groundwork for clinical testing.
CRISTAL-APC is jointly sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, and is being delivered by the Cambridge Clinical Trials Unit through its Early Phase Cancer Portfolio. This partnership brings together leading research, clinical leadership, and trial delivery expertise to advance new treatment possibilities for patients facing pancreatic cancer.
For general enquiries or questions please contact
[email protected]
